Is the targeted drug Sacituzumab govitecan a Todavi drug?

The targeted drug Sacituzumab govitecanThe original drug is marketed in China as gosatuzumab for injection. Its trade name is TRODELVY, which belongs to a class of anti-cancer drugs. The drug has also been approved by the U.S. Food and Drug Administration (FDA) for marketing overseas under the trade name TRODELVY.

Gosatuzumab is indicated for the treatment of breast cancer in adults who have been previously treated with endocrine therapy and at least two other cancer drugs. Gosatuzumab is also used in adults to treat bladder and urinary tract cancers after treatment with platinum cancer drugs and immunotherapy. Gosatuzumab is used when the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery. Gosatuzumab may also be used for purposes not listed in this Medication Guide,but continued approval may be contingent on demonstration of clinical benefit in confirmatory trials. The most common side effects include neutropenia, nausea, diarrhea, fatigue, alopecia, anemia (which may cause fatigue and pale skin), constipation, vomiting, decreased appetite, difficulty breathing, and abdominal pain.

Gosatuzumab The original drug has been launched in China, but it has not yet been included in the medical insurance. The price of a 100mg bottle may be around 10,000 yuan, which is relatively expensive. Gosatuzumab Original drug marketed overseas has three versions: European version, American version, and Singapore version. SpecificationsThe price of each 100 mg bottle may be around RMB 10,000-35,000 (the price may fluctuate due to exchange rates). The ingredients of gosatuzumab sold domestically and abroad are basically the same. There is currently no generic version of gosatuzumab available on the market. For specific prices and drug information, please consult your medical consultant.